Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:00607595 | Esophagus | ESCC | regulation of response to cytokine stimulus | 103/8552 | 162/18723 | 3.14e-06 | 3.53e-05 | 103 |
GO:00019595 | Esophagus | ESCC | regulation of cytokine-mediated signaling pathway | 95/8552 | 150/18723 | 9.48e-06 | 9.04e-05 | 95 |
GO:00301984 | Esophagus | ESCC | extracellular matrix organization | 171/8552 | 301/18723 | 6.08e-05 | 4.67e-04 | 171 |
GO:00430624 | Esophagus | ESCC | extracellular structure organization | 171/8552 | 302/18723 | 7.73e-05 | 5.76e-04 | 171 |
GO:00452294 | Esophagus | ESCC | external encapsulating structure organization | 172/8552 | 304/18723 | 7.80e-05 | 5.80e-04 | 172 |
GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
GO:007259318 | Esophagus | ESCC | reactive oxygen species metabolic process | 137/8552 | 239/18723 | 1.82e-04 | 1.16e-03 | 137 |
GO:1990748110 | Esophagus | ESCC | cellular detoxification | 70/8552 | 116/18723 | 1.02e-03 | 5.17e-03 | 70 |
GO:00301993 | Esophagus | ESCC | collagen fibril organization | 40/8552 | 61/18723 | 1.35e-03 | 6.44e-03 | 40 |
GO:0097237110 | Esophagus | ESCC | cellular response to toxic substance | 72/8552 | 124/18723 | 3.65e-03 | 1.49e-02 | 72 |
GO:0098869110 | Esophagus | ESCC | cellular oxidant detoxification | 60/8552 | 101/18723 | 3.76e-03 | 1.53e-02 | 60 |
GO:00717115 | Esophagus | ESCC | basement membrane organization | 22/8552 | 31/18723 | 3.90e-03 | 1.58e-02 | 22 |
GO:00850292 | Esophagus | ESCC | extracellular matrix assembly | 29/8552 | 45/18723 | 8.63e-03 | 3.04e-02 | 29 |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:00019594 | Oral cavity | OSCC | regulation of cytokine-mediated signaling pathway | 87/7305 | 150/18723 | 1.82e-06 | 2.35e-05 | 87 |
GO:00607594 | Oral cavity | OSCC | regulation of response to cytokine stimulus | 92/7305 | 162/18723 | 3.25e-06 | 3.90e-05 | 92 |
GO:000963618 | Oral cavity | OSCC | response to toxic substance | 137/7305 | 262/18723 | 7.94e-06 | 8.52e-05 | 137 |
GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
GO:00192214 | Oral cavity | OSCC | cytokine-mediated signaling pathway | 222/7305 | 472/18723 | 2.02e-04 | 1.35e-03 | 222 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PXDN | SNV | Missense_Mutation | novel | c.1537N>T | p.Val513Phe | p.V513F | Q92626 | protein_coding | deleterious(0.03) | possibly_damaging(0.616) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR |
PXDN | SNV | Missense_Mutation | rs536136666 | c.3542N>T | p.Ala1181Val | p.A1181V | Q92626 | protein_coding | tolerated(0.65) | benign(0.108) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
PXDN | SNV | Missense_Mutation | | c.2951N>C | p.Leu984Pro | p.L984P | Q92626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
PXDN | SNV | Missense_Mutation | novel | c.3496N>A | p.Gly1166Arg | p.G1166R | Q92626 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-JL-A3YX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PXDN | insertion | Frame_Shift_Ins | novel | c.672_673insAT | p.Pro225IlefsTer18 | p.P225Ifs*18 | Q92626 | protein_coding | | | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
PXDN | insertion | Nonsense_Mutation | novel | c.3700_3701insAAGCTGACACAGCTTAGAGA | p.Cys1234Ter | p.C1234* | Q92626 | protein_coding | | | TCGA-A8-A081-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PXDN | insertion | Nonsense_Mutation | novel | c.2003_2004insAATAATTT | p.Tyr668Ter | p.Y668* | Q92626 | protein_coding | | | TCGA-AC-A3QQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PXDN | insertion | Frame_Shift_Ins | novel | c.3901_3902insTATTTAATTTAGTAAGCGTTGAAATCTGCACTGATAATAG | p.Cys1301LeufsTer15 | p.C1301Lfs*15 | Q92626 | protein_coding | | | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
PXDN | SNV | Missense_Mutation | novel | c.1841C>A | p.Pro614His | p.P614H | Q92626 | protein_coding | tolerated(0.06) | possibly_damaging(0.76) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PXDN | SNV | Missense_Mutation | novel | c.1435C>T | p.His479Tyr | p.H479Y | Q92626 | protein_coding | tolerated(0.3) | probably_damaging(0.943) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |